Abstract library

10 results for "Hsu".
#336 Overall Survival (OS) Analysis of Sunitinib (SU) After Adjustment for Crossover (CO) in Patients With Pancreatic Neuroendocrine Tumors (NET)
Introduction: A recent phase 3 trial of SU in pancreatic NET showed an improvement in progression-free survival (PFS) and OS. However, the OS benefit was confounded by early CO from placebo (PBO) to SU treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jack Ishak
#538 Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales
Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Adam Johns
Authors: Johns A, Eatock M, Johal S, ...
#1871 Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines
Introduction: Su has shown PFS improvement in patients (pt) with PNET in phase III trial
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib
#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)
Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Raymond
#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Keywords: sutent, OS
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler
#1760 The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Authors: Raymond E, Kulke M H, Qin S, Yu X, ...
Keywords: pNET, survival, sunitinib
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
#813 Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index for Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki-67Counter)
Introduction: Ki-67 proliferation index is an increasingly important biomarker used to grade neuroendocrine tumors. Manual counting methods are laborious and subject to inter- and intra-observer variability. Digital counting methods hold promise for fast and reproducible indices, however, they are fraught with technical difficulties.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. Lin Yang
Authors: Neltner J, Su H, Xing F, Rosser J, ...
#1697 An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Authors: Xu J, Li J, Bai C M, Xu N, ...
Keywords: sulfatinib, net, orr, pfs